SYNGR2

Across TCGA pan-cancer cohorts, SYNGR2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SYNGR2 data layer compared with 28 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SYNGR2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SYNGR2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, CCRCC, and GBM are the cancer types where SYNGR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Quartile	All	1.000	0.827	.020	22	view →
CCRCC	OS	Tertile	All	0.766	0.967	.005	16	view →
GBM	OS	Tertile	All	0.359	0.712	<.001	14	view →
PDAC	OS	Median	III,IV	0.276	0.837	.001	13	view →
HNSC	DFS	Median	IV	0.924	1.000	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SYNGR2–UCEC (OS)

Open the UCEC breakdown →